Novavax Stock Forecast, Price & News

-20.64 (-9.94 %)
(As of 06/15/2021 05:29 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume6.80 million shs
Average Volume4.14 million shs
Market Capitalization$13.86 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

Novavax logo

About Novavax

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.56 out of 5 stars

Medical Sector

790th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

112th out of 198 stocks

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Novavax (NASDAQ:NVAX) Frequently Asked Questions

Is Novavax a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax
or view top-rated stocks.

What stocks does MarketBeat like better than Novavax?

Wall Street analysts have given Novavax a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novavax wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Novavax

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings results on Monday, May, 10th. The biopharmaceutical company reported ($3.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.65) by $0.40. The biopharmaceutical company had revenue of $447 million for the quarter, compared to analyst estimates of $233.90 million. Novavax had a negative trailing twelve-month return on equity of 125.71% and a negative net margin of 66.90%. The business's revenue was up 13124.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.58) EPS.
View Novavax's earnings history

How has Novavax's stock been impacted by Coronavirus?

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVAX shares have increased by 1,683.1% and is now trading at $187.40.
View which stocks have been most impacted by COVID-19

When did Novavax's stock split? How did Novavax's stock split work?

Shares of Novavax reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

6 brokerages have issued 12 month target prices for Novavax's shares. Their forecasts range from $105.00 to $294.00. On average, they expect Novavax's share price to reach $225.50 in the next twelve months. This suggests a possible upside of 20.3% from the stock's current price.
View analysts' price targets for Novavax
or view top-rated stocks among Wall Street analysts.

Who are Novavax's key executives?

Novavax's management team includes the following people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 73, Pay $1.26M) (LinkedIn Profile)
  • Mr. John Joseph Trizzino, Exec. VP, Interim CFO, Chief Bus. & Commercial Officer & Treasurer (Age 61, Pay $676.83k)
  • Mr. John A. Herrmann III, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 55, Pay $655.95k) (LinkedIn Profile)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 67, Pay $857.42k)
  • Mr. Richard P. Crowley, Exec. VP & COO (Age 64)
  • Dr. Gale E. Smith, Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist (Age 71)
  • Mr. Biegie Lee, Sr. VP & Chief Information Officer
  • Ms. Silvia Taylor M.B.A., MBA, Sr. VP of Investor Relations & Corp. Affairs
  • Mr. Troy Morgan Esq., Sr. VP & Chief Compliance Officer (Age 50)
  • Ms. Erika S. Trahan, Associate Director of Investor & PR

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax CEO Stanley C. Erck on Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Who are some of Novavax's key competitors?

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different institutional and retail investors. Top institutional investors include RA Capital Management L.P. (4.05%), Franklin Resources Inc. (1.76%), Geode Capital Management LLC (1.50%), Price T Rowe Associates Inc. MD (1.11%), Northern Trust Corp (1.08%) and Renaissance Technologies LLC (0.91%). Company insiders that own Novavax stock include Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax

Which major investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including Amundi Asset Management US Inc., RA Capital Management L.P., Northern Trust Corp, Rock Springs Capital Management LP, Schroder Investment Management Group, Sectoral Asset Management Inc, TSP Capital Management Group LLC, and Baker BROS. Advisors LP. Company insiders that have sold Novavax company stock in the last year include Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax
or view top insider-selling stocks.

Which major investors are buying Novavax stock?

NVAX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, Cormorant Asset Management LP, Capital International Investors, Orbimed Advisors LLC, Geode Capital Management LLC, Rothschild & Co. Asset Management US Inc., and Polar Capital Holdings Plc. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax
or or view top insider-buying stocks.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $187.40.

How much money does Novavax make?

Novavax has a market capitalization of $13.88 billion and generates $475.60 million in revenue each year. The biopharmaceutical company earns $-418,260,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis.

How many employees does Novavax have?

Novavax employs 792 workers across the globe.

When was Novavax founded?

Novavax was founded in 1987.

What is Novavax's official website?

The official website for Novavax is

Where are Novavax's headquarters?

Novavax is headquartered at 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]

This page was last updated on 6/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.